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Abstract
Background: Increased number of single nucleotide substitutions is seen in breast and ovarian cancer genomes
carrying disease-associated mutations in BRCA1 or BRCA2. The significance of these genome-wide mutations is
unknown. We hypothesize genome-wide mutation burden mirrors deficiencies in DNA repair and is associated with
treatment outcome in ovarian cancer.
Methods and Results: The total number of synonymous and non-synonymous exome mutations (Nmut), and the
presence of germline or somatic mutation in BRCA1 or BRCA2 (mBRCA) were extracted from whole-exome
sequences of high-grade serous ovarian cancers from The Cancer Genome Atlas (TCGA). Cox regression and
Kaplan-Meier methods were used to correlate Nmut with chemotherapy response and outcome. Higher Nmut
correlated with a better response to chemotherapy after surgery. In patients with mBRCA-associated cancer, low
Nmut was associated with shorter progression-free survival (PFS) and overall survival (OS), independent of other
prognostic factors in multivariate analysis. Patients with mBRCA-associated cancers and a high Nmut had
remarkably favorable PFS and OS. The association with survival was similar in cancers with either BRCA1 or BRCA2
mutations. In cancers with wild-type BRCA, tumor Nmut was associated with treatment response in patients with no
residual disease after surgery.
Conclusions: Tumor Nmut was associated with treatment response and with both PFS and OS in patients with high-
grade serous ovarian cancer carrying BRCA1 or BRCA2 mutations. In the TCGA cohort, low Nmut predicted
resistance to chemotherapy, and for shorter PFS and OS, while high Nmut forecasts a remarkably favorable outcome
in mBRCA-associated ovarian cancer. Our observations suggest that the total mutation burden coupled with BRCA1
or BRCA2 mutations in ovarian cancer is a genomic marker of prognosis and predictor of treatment response. This
marker may reflect the degree of deficiency in BRCA-mediated pathways, or the extent of compensation for the
deficiency by alternative mechanisms.
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Introduction
Reliable biomarkers predicting resistance or sensitivity to
anti-cancer therapy facilitate selection of proper therapeutic
drugs in individual cancer patients. In breast cancer, the
estrogen receptor and HER2 (erbB-2/neu) are used clinically to
make therapeutic decisions about endocrine therapy and
HER2-targeted drugs, respectively [1,2]. Both the estrogen
receptor and HER2 participate in pathways that promote
cancer growth. Likewise, BRCA1 and BRCA2 participate in
error-free repair of double-strand DNA breaks by homologous
recombination (HR) and inherited mutations in these genes
predispose to breast and ovarian cancers [3]. Ovarian cancers
carrying BRCA1 and BRCA2 mutations (mBRCA) display
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massive chromosomal alterations [4,5], and are more sensitive
to DNA cross-linking agents containing platinum, and to PARP
inhibitors [6,7]. Patients with high-grade serous ovarian cancer
who carry germline mBRCA experience a longer progression-
free survival (PFS) and better overall survival (OS) than non-
carriers [6,8,9]. Therefore, BRCA1 and BRCA2 may be
considered biomarkers that predict response to platinum-
containing chemotherapy and to PARP inhibitors. However, in
previous studies 15-18 % of BRCA-associated ovarian cancers
responded poorly to platinum-based chemotherapy regimens,
and either recurred or progressed shortly after initial surgery
and chemotherapy [8,9].
Most sporadic high-grade serous ovarian cancer and triple-
negative breast cancer do not have mutations in BRCA genes,
but a subset of these tumors do exhibit massive chromosomal
aberrations and responsiveness to DNA damaging
chemotherapy [9-11]. An appealing hypothesis posits
chromosomal aberrations are a gauge of the degree of
impairment in HR. Proposed surrogates for HR defects include
measures of chromosomal aberrations including whole genome
loss of heterozygosity (LOH) and telomeric allelic imbalance
[11,12]. Lack of Rad51 foci after DNA damage may also mark
cells with impaired HR [13].
Recently, a significantly higher mutation burden was
detected by whole genome or exome sequencing in breast and
ovarian cancer with mBRCA, compared with their counterparts
carrying the wild-type BRCA1 and BRCA2 (wtBRCA) genes
[14,15]. Whole exome sequencing of high-grade serous
ovarian cancers was reported by The Cancer Genome Atlas
(TCGA) consortium[9]. The DNA sequence of ovarian cancers
was compared to germline DNA sequence from the same
subject to make somatic mutation calls. Identified mutations
included base substitutions, insertions or deletions [9,15]. The
vast majority of mutations were single base substitutions [9].
Accumulation of genome-wide mutations may be the
consequence of unique mutational processes associated with
DNA repair deficiency in tumors carrying BRCA1 or BRCA2
mutations.
Since ovarian cancers with mutations in BRCA1 or BRCA2
are more sensitive to platinum-containing chemotherapy, we
asked whether the total number of somatic mutations in ovarian
cancer predicts sensitivity to chemotherapy and clinical
outcome. We used whole exome sequencing data from TCGA
to enumerate somatic mutations and compared this to
chemotherapy sensitivity, progression free survival (PFS) and
overall survival (OS). A significant association between the
total number of somatic exome mutations per genome (Nmut)
and patient outcomes was observed in patients whose ovarian
cancers possessed mutations in BRCA1 and BRCA2.
Results
Association of mutation burden with chemotherapy
sensitivity and outcome
Using data from TCGA, we found that 95% of mutations in
exomes of ovarian cancer are single base substitutions. Across
the TCGA cohort of 316 tumors, the number of exome
mutations in individual cancers (Nmut) varies widely, from 9 to
210 (median 54.5, Table S1). To determine whether Nmut is
associated with chemotherapy resistance after initial surgery,
we separated patients into Nmut high and low groups based on
the median Nmut of the whole cohort. A higher rate of
resistance to initial chemotherapy was observed in Nmut low
compared to the Nmut high group (40.2 vs. 23.9 %, Figure 1A).
Nmut was lower in treatment-resistant patients than sensitive
patients (median 46 vs. 59, Figure 1B). Cox regression showed
a correlation between Nmut and progression-free survival
(PFS) or overall survival (OS) (P = 0.013 and 0.0014,
respectively, Table 1). Kaplan-Meier analysis showed a
significantly longer PFS and OS in the Nmut high group
compared to the Nmut low group (Figure 1C and 1D).
Effect of BRCA1 and BRCA2 on mutation burden and
outcome
Seventy patients either carried a germline BRCA1 or BRCA2
mutation or possessed tumors bearing somatic BRCA1 or
BRCA2 mutations (mBRCA). We found no differences in tumor
Nmut, PFS or OS between patients with germline and tumor
somatic mutations in BRCA1 and BRCA2 (Figure S1).
However, mBRCA-associated tumors possessed a higher
Nmut than tumors without BRCA mutations (wtBRCA; median
67.5 vs. 49.5, Figure S2A). We separately analyzed the subset
of patients bearing mBRCA and those with wtBRCA tumors,
and compared tumor Nmut between chemotherapy resistant
and sensitive patients. A higher tumor Nmut predicted a higher
rate of response to chemotherapy after surgery in patients with
mBRCA-associated tumors, but not in those with tumors that
possessed only wtBRCA (Figures S2B and S2C). When we
investigated all patients with tumors containing mBRCA, we
found a significantly higher tumor Nmut in the treatment-
sensitive group versus the treatment-resistant group (median
74 vs. 44, Figure 2A). In patients with wtBRCA tumors, there
were no significant differences in Nmut between the treatment
sensitive and resistant groups (median 52 vs. 47, Figure 2B).
Cox regression showed a significant correlation between tumor
Nmut and PFS and OS in patients with mBRCA-associated
tumors (HR = 0.82, P = 0.002 and HR = 0.83, P = 0.011,
respectively), but not in patients with wtBRCA tumors (Table 1).
When patients with mBRCA-associated tumors were stratified
by the median Nmut of the whole cohort, patients with high
tumor Nmut showed a significantly longer PFS and OS (Figure
2C and 2D). PFS and OS in patients with mBRCA and low
tumor Nmut were shorter, similar to patients with wtBRCA
tumors (Figure 2C to 2F). In patients with wtBRCA tumors,
there was no significant relationship between Nmut and PFS or
OS (Figure 2E and 2F). Therefore, the effect of tumor Nmut on
treatment response and outcome was chiefly confined to those
tumors with either germline or somatic mutations in BRCA1 or
BRCA2.
In univariate and multivariate analysis, stage at presentation,
size of residual tumors after debulking surgery, patient age and
Nmut were associated with either PFS or OS in all patients with
clinical follow-up (Table 1). Strikingly, for the patients with
mBRCA-associated ovarian cancer, only Nmut was
significantly associated with treatment outcome in both
univariate and multivariate analysis. In multivariate analysis of
Mutation and Outcome in Ovarian Cancer Patients
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cancers with wtBRCA, residual disease left after initial surgery
was significantly associated with both PFS and OS. Nmut and
age were significantly associated with OS, but not PFS in
patients with wtBRCA (Table 1). These results show Nmut is
significantly associated with clinical outcome and is
independent of other prognostic factors in patients with
mBRCA-associated tumors.
All 51 germline mutations in BRCA1 and BRCA2 were
truncating mutations. Of the 21 somatic mutations in the two
genes, 4 were missense and the others truncating. We
examined location of the mutations in BRCA1 and BRCA2
genes for association with Nmut in tumors (Figures S3A and
S3B). We separated BRCA mutations into ring, middle and
BRCT domains of BRCA1 and N-terminal, RAD51 binding and
C-terminal regions of BRCA2. Differences in Nmut among
Figure 1.  Total number of exome mutations (Nmut) and clinical outcome in high-grade serous ovarian cancer.  All patients
received platinum and most received taxanes in combination. A) Tumors were separated into Nmut high and low groups defined by
the median Nmut across the whole cohort and compared to the rate of chemotherapy resistance. The significance of the differences
was determined by Fisher’s exact test. B) The number of mutations (Nmut) for each tumor was compared in chemotherapy resistant
and sensitive patients and is shown by dot plots. Median and 25-75 percentiles are indicated by horizontal lines. P-value is derived
from the Wilcoxon rank-sum test. C) Kaplan-Meier analysis compared the progression-free survival (PFS) and D) overall survival
(OS) between patients with high and low tumor Nmut. Patients that were progression-free or still alive at the time of last follow-up
were censored (+). Numbers of patients at risk at each interval are given below the graphs. P-values are obtained by Log-rank test.
doi: 10.1371/journal.pone.0080023.g001
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tumors with mutations in these regions of BRCA1 and BRCA2
were evaluated. No significant association was found between
Nmut and mutations in different regions of BRCA1 or BRCA2
(Kruskal-Wallis test for multiple comparisons, P = 0.58 and P =
0.13, Figures S3C and S3D).
Fourteen mBRCA-associated tumors (6 somatic and 8
germline BRCA mutations) remained heterozygous at the
mutated BRCA locus (Table S1). To avoid the influence of the
wtBRCA allele, we tested for the association between tumor
Nmut and clinical outcome in the subset of patients carrying
BRCA germline mutations with LOH at the corresponding
BRCA locus in their tumors. Cox regression revealed a
significant correlation between Nmut and OS (HR = 0. 765, P =
0.021) and a trend toward significant correlation between Nmut
and PFS (HR = 0. 837, P = 0.056). Kaplan-Meier analysis
displays the remarkable differences in outcome between
patients with high and low tumor mutation burden (Figure 3A
and 3B). Despite small numbers, significant and consistent
differences in PFS and OS were seen when BRCA1 and
BRCA2 germline mutation carriers were evaluated separately
(Figure 3C to 3F). These results support the conclusion that
tumor Nmut is associated with both treatment response and
clinical outcome within patients with inherited BRCA1 or
BRCA2 mutations.
We examined Nmut in tumors with known epigenetic
changes in BRCA1 (n = 31) and RAD51C (n = 8) in this TCGA
dataset. Compared to tumors with wtBRCA and without
methylation in the two genes, we observed a higher Nmut in
tumors with BRCA1 or RAD51C methylation, similar to tumors
with mBRCA (Figure S4). The result suggests that epigenetic
silencing in BRCA1 and RAD51C may lead to accumulation of
single base substitutions. However, in agreement with
previously published results [9,15], the outcomes (PFS and
OS) of patients with tumors harboring BRCA1 methylation
coupled with high Nmut were similar to patients whose tumors
had low Nmut or wtBRCA1 (data not shown). The association
between tumor Nmut and treatment outcome appears largely in
Table 1. Univariate and Multivariate analysis of Nmut and other clinical variables with PFS and OS.
  Univariate  Multivariate
  HRa 95% CIb Pc  HR 95% CI P
All cases
Nmutd PFS 0.944 (0.990-0.999) 0.013  0.955 (0.991-1.000) 0.042
 OS 0.926 (0.988-0.997) 0.0014  0.913 (0.986-0.996) 0.0001
Stage PFS 1.466 (1.072-2.005) 0.017  1.38 (0.985-1.935) 0.061
 OS 1.325 (0.960-1.828) 0.087  1.221 (0.865-1.724) 0.256
Residuale PFS 1.183 (1.026-1.365) 0.021  1.158 (0.999-1.342) 0.052
 OS 1.267 (1.091-1.470) 0.0019  1.245 (1.065-1.455) 0.006
Age (yrs) PFS 0.995 (0.982-1.009) 0.492  0.998 (0.984-1.013) 0.828
 OS 1.019 (1.005-1.033) 0.0075  1.025 (1.010-1.040) 0.001
Mbrca
Nmut PFS 0.817 (0.968-0.993) 0.002  0.856 (0.971-0.998) 0.027
 OS 0.828 (0.967-0.996) 0.011  0.821 (0.966-0.995) 0.0082
Stage PFS 1.694 (0.745-3.853) 0.209  1.415 (0.600-3.338) 0.428
 OS 1.304 (0.539-3.154) 0.555  1.1 (0.396-3.055) 0.856
Residual PFS 0.999 (0.723-1.379) 0.993  0.979 (0.695-1.379) 0.904
 OS 1.362 (0.959-1.936) 0.084  1.389 (0.961-2.009) 0.081
Age (yrs) PFS 0.987 (0.960-1.016) 0.378  0.999 (0.967-1.031) 0.928
 OS 1.017 (0.985-1.049) 0.301  1.023 (0.990-1.058) 0.175
wtBRCA
Nmut PFS 0.987 (0.994-1.003) 0.593  0.989 (0.994-1.004) 0.648
 OS 0.966 (0.992-1.001) 0.159  0.948 (0.990-1.000) 0.032
Stage PFS 1.369 (0.980-1.913) 0.065  1.234 (0.859-1.772) 0.255
 OS 1.224 (0.871-1.719) 0.244  1.119 (0.778-1.608) 0.545
Residual PFS 1.231 (1.048-1.447) 0.011  1.219 (1.030-1.443) 0.021
 OS 1.195 (1.011-1.414) 0.037  1.192 (1.000-1.421) 0.051
Age (yrs) PFS 0.994 (0.979-1.010) 0.466  0.998 (0.982-1.015) 0.841
 OS 1.017 (1.001-1.033) 0.035  1.024 (1.007-1.041) 0.0051
a. Hazard ratio
b. 95% confidence interval
c. P-value from Cox proportional hazard regression
d. HR for Nmut is expressed the ratio per 10 mutations
e. Residual disease left after initial surgery
doi: 10.1371/journal.pone.0080023.t001
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Figure 2.  Total number of exome mutations (Nmut) and clinical outcome in high-grade serous ovarian cancer with
germline or somatic mutations in BRCA1 or BRCA2 (mBRCA) or with wild-type BRCA1 and BRCA2 (wtBRCA).  A) Nmut in
tumors with mBRCA. Chemotherapy resistant and sensitive ovarian cancers are shown by dot plots. P-value is derived from the
Wilcoxon rank-sum test. B) Nmut in tumors with wtBRCA. Chemotherapy resistant and sensitive tumors are shown with dot plots of
each tumor as in Figure 1. Median and 25-75 percentiles are indicated by horizontal lines. P-value is derived from Wilcoxon rank-
sum test. C) Kaplan-Meier analysis compared PFS and D) OS between patients with high and low Nmut in their mBRCA-associated
tumors. E) Kaplan-Meier analysis compared PFS and F) OS in patients with high and low Nmut in their wtBRCA tumors. The
median for Nmut was computed from the whole cohort of 316 tumors. In Kaplan-Meier analyses, patients that were progression-free
or still alive at the time of last follow-up were censored (+). Numbers of patients at risk at each interval are given below the graphs.
P-values are obtained from Log-rank test.
doi: 10.1371/journal.pone.0080023.g002
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Figure 3.  Tumor Nmut and clinical treatment outcome in ovarian cancer patients carrying BRCA germline mutations with
LOH at the BRCA loci in tumors.  A) Kaplan-Meier analysis compared PFS and B) OS between Nmut high and low ovarian
cancers, all of which carried either a BRCA1 or BRCA2 germline mutation with LOH at the corresponding BRCA locus. C - F)
Analysis in individual BRCA1 and BRCA2 mutation carrier groups. C) Kaplan-Meier analysis in patients with BRCA1-associated
tumors comparing PFS, and D) OS. E) Kaplan-Meier analysis in patients with BRCA2-associated tumors comparing PFS, and F)
OS. Nmut high and low are defined as a value above or below median Nmut of all mBRCA-associated tumors. Numbers of patients
at risk at each interval are given below the graphs. P-values are calculated by log-rank test.
doi: 10.1371/journal.pone.0080023.g003
Mutation and Outcome in Ovarian Cancer Patients
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cancers with BRCA1 mutation, but not in those cancer with
BRCA1 epigenetic alteration.
Correlation between Nmut and age or chromosomal
damage
Nmut in tumors from patients with germline BRCA1 or
BRCA2 mutations (BRCA mutations) increased with patient
age at diagnosis (Figure S5A). However, this relationship was
lost when tumors with somatic BRCA mutations were included
or those with wtBRCA were analyzed separately, (Figures S5B
and S5C). These finding are consistent with a distinct
pathogenic process in germline BRCA-associated cancers with
haplo-insufficiency of BRCA function in premalignant tissue,
and those cancers that acquire BRCA mutations later in their
development. A similar correlation between accumulated
mutations and age was reported in cancers that arise from
tissues which normally replicate during life (e.g., colonic
epithelium), but are not seen in cancers from tissue normally
dormant (e.g., cells in the exocrine pancreas)[16].
Both the fraction of LOH per genome (FLOH) and the
number of episodes of telomeric allelic imbalance (NtAI) reflect
the extent of tumor chromosomal damage [11,12]. Using TCGA
SNP6 data from the same cohort, Nmut positively correlated
with FLOH and NtAI in mBRCA-associated tumors; NtAI
correlated with Nmut in wtBRCA tumors (Figure S6). The
association between high mutation burden and high level of
chromosomal damage suggests a link between the processes
that produce or fail to repair these distinct types of DNA
damage.
Influence of residual disease on the association of
mutation burden and outcome
Residual disease after initial surgery is a prognostic factor in
ovarian cancer and was confirmed in both mBRCA- and
wtBRCA-associated ovarian cancer (Figure S7). In patients
with mBRCA-related cancers, those with a high tumor Nmut
had better outcomes than those with a low tumor Nmut
regardless of whether residual disease was present after initial
surgery (Figure S8). Patients with no residual disease and a
high tumor Nmut had an especially favorable outcome (5 year
PFS was 58% and OS was 100%; Figure S8). In the subset of
patients with wtBRCA tumors and no residual disease after
surgery, high tumor Nmut predicted a longer PFS and a trend
towards longer OS (Figure 4). No such differences were found
in patients with wtBRCA tumors and residual disease after
surgery (data not shown). Residual disease is a powerful
prognostic factor, which may mask the effect of tumor Nmut in
patients with wtBRCA tumors. The result suggests Nmut is
potentially associated with treatment outcome in sporadic
ovarian cancer with wtBRCA and no residual disease.
Figure 4.  Nmut and treatment outcome in patients with wtBRCA tumors and no residual disease after initial surgery.  Nmut
high and low were defined by values above or below the median Nmut from all wtBRCA tumors in the cohort. A) Kaplan-Meier
analysis compared PFS, and B) OS between tumor Nmut high and low in patients with wtBRCA tumors and no residual disease
after debulking surgery. Numbers of patients at risk at each interval are given below the graphs. P-values are obtained from Log-
rank test.
doi: 10.1371/journal.pone.0080023.g004
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Discussion
High-grade serous ovarian cancer in carriers of BRCA1 or
BRCA2 has a better prognosis than the same disease in non-
carriers, and may be more sensitive to cisplatin-based
chemotherapy or to PARP inhibitors that target DNA repair
[6-8]. However, within the group of women with somatic or
inherited mutations in BRCA1 or BRCA2, some patients will still
have poor outcomes. There are currently no markers of
treatment outcome in patients with mBRCA-associated ovarian
cancer. Possible markers might include impaired apoptosis,
multi-drug resistance and DNA repair proficiency. The present
study sought to correlate whole-exome mutation burden in
tumor tissue (Nmut) to treatment outcome in ovarian cancer
patients, and to examine this relationship in patients with
BRCA1 and BRCA2 mutations in their ovarian tumors.
The most remarkable association of Nmut with treatment
response and outcome was seen within the subset of patients
with mBRCA-associated tumors. A substantial proportion of
patients with mBRCA-associated ovarian cancer but low Nmut
experienced a relatively poor treatment outcome, and similar to
patients with wtBRCA ovarian cancer. However, for women
whose cancers were mBRCA-associated and had a high tumor
Nmut, outcome was remarkably good. This was true for both
BRCA1 and BRCA2 mutations, both germline and somatic
mutations, and for tumors with LOH at the corresponding locus.
In patients with mBRCA-associated cancers and no residual
disease after initial surgery, those with high Nmut had
especially good outcomes. In fact, long survival in high-grade
serous ovarian cancer, when it is observed, may be attributable
to mutation in either BRCA1 or BRCA2 when these genotypes
are coupled with a high tumor Nmut. Nmut is a candidate
genomic marker for predicting treatment outcome in patients
with mBRCA-associated ovarian cancer. The association of
Nmut and outcome may reflect the degree of deficiency in
BRCA1- or BRCA2-mediated DNA repair pathway(s), or the
result of compensation for the deficiency by alternative
mechanisms. However, all of the patients in the TCGA cohort
received platinum-based chemotherapy, and the beneficial
effect of a BRCA1 or BRCA2 deficiency on OS may be due to
improved treatment response, or due to the less lethal potential
of mBRCA-associated cancers.
In our analysis of TCGA data, BRCA1 mutation-associated
ovarian cancer had a better outcome when coupled with a high
tumor Nmut. In addition, BRCA1 mutation-associated cancer
that lost the wild-type BRCA1 allele had a better outcome than
ovarian cancer with only wild-type BRCA1 (data not shown). It
is unclear why BRCA1 methylation, even coupled with high
Nmut, does not translate into the same survival benefit seen in
ovarian cancer with BRCA mutations and high Nmut. BRCA1
methylation is associated with a significant decrease of BRCA1
transcript levels, higher levels of genome-wide LOH and, in this
study, higher mutation burden [9,11,15]. Under selection of
platinum treatment, it is possible BRCA1 methylation may be
reversible, and lead to the restoration of BRCA1 expression. In
breast cancer xenografts, therapy resistant triple-negative
cancer lost BRCA1 promoter methylation and re-expressed the
BRCA1 protein [17]. The epigenetic co-inactivation of other
gene(s), for instance in pro-apoptotic pathway(s), is a
possibility that could explain the worse outcome of patients with
BRCA1 methylation compared to those with BRCA1 mutation.
These possibilities remain open to future studies.
Next-generation DNA sequencing is widely used in research
and may become a clinical tool to detect specific and targetable
mutations. A by-product of the increased use of whole-genome
and whole exome sequencing studies may be a simple
enumeration of genome-wide mutations, which may itself
represent a genomic biomarker for predicting outcomes in
patients receiving optimal surgery and chemotherapy.
Our observations are consistent with the concept that
BRCA1 and BRCA2 regulate error-free repair of nucleotide
damage and act to minimize single nucleotide mutations. There
is evidence of BRCA1 DNA repair activity in pathways other
than HR. Pathania, et al demonstrated BRCA1 played a role in
repair of UV radiation-damaged DNA. BRCA1 participated in
DNA replication-dependent but nucleotide excision repair
(NER)-independent repair processes by promoting
photoproduct excision and suppression of error-prone
translesion synthesis (TLS) at UV-induced stalled replication
forks [18]. High activity of TLS may be induced by FANCJ
activity when there is loss of BRCA1 binding to FANCJ [19]. As
TLS polymerases are error-prone, an up-regulation of TLS in
the setting of BRCA1 deficiency may explain a higher rate of
somatic nucleotide substitutions.
Whole genome sequencing in breast cancer identified a
characteristic distribution of single nucleotide mutations with an
increased overall mutation burden in both BRCA1- and
BRCA2-associated tumors. All possible nucleotide substitutions
were seen within 96 possible trinucleotide sequence contexts
without predominant patterns of particular trinucleotides, which
was a characteristic signature of both BRCA1- and BRCA2-
associated breast cancers [14]. This characteristic appears
consistent with loss of a key mechanism(s) for error-free DNA
repair in addition to HR, or activation of an error-prone DNA
replication process.
Other lines of evidence show differences between BRCA1
and BRCA2 mutation-associated ovarian cancers. These
differences include relatively earlier onset in BRCA1 than
BRCA2 germline mutation carriers, and a relatively better
survival in patients with BRCA2 than BRCA1 mutation-
associated tumors in comparison to that in patients with
wtBRCA-associated ovarian cancer [6,15]. Our results show
the same associations between tumor Nmut and treatment
outcome in both BRCA1- and BRCA2-associated ovarian
cancers. This observation is consistent with similar signatures
of mutational processes in breast and ovarian cancers from
patients with either BRCA1 or BRCA2 germline mutations
[14,20]. There are other well-recognized similarities between
BRCA1- and BRCA2-associated diseases. These similarities
include HR-mediated DNA repair deficiencies, sensitivity to
DNA damaging agents and PARP inhibitors, and reversion
mutation-associated treatment resistance [3,6,7,9,21,22].
A low mutation burden in tumors with either a homozygous
BRCA1 or BRCA2 damaging mutation and LOH at the
corresponding BRCA locus may be explained by activation of
alternative mechanism(s) capable of bypassing the defect and
Mutation and Outcome in Ovarian Cancer Patients
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restoring error-free DNA repair. Our knowledge of bypass
pathways of repair is limited. Alternative activation of HR by
concomitant loss of 53BP1 in BRCA1-deficient cells may
restore resistance to PARP inhibitors, but does not change the
sensitivity to cisplatin [23,24]. Reversion mutation of BRCA1/2
genes in recurrent disease may result in resistance to platinum
chemotherapy and PARP inhibitors, but is rarely found in the
primary disease [21]. Our results are based on a relatively
small set of patients carrying BRCA1 and BRCA2 mutations,
and should be considered hypothesis generating until
confirmed in a larger cohort. In addition, tumors may possess
de novo mechanisms leading to resistance to chemotherapy
and targeted treatments. Our preliminary results suggest low
tumor Nmut may identify BRCA-associated primary tumors in
which the original deficiency of BRCA1 and BRCA2 pathways,
including impaired DNA repair, is compensated for by
alternative pathways.
Materials and Methods
Datasets
We obtained exome sequencing data of 316 high-grade
serous ovarian cancers and follow-up information from TCGA
[9]. Any sequence alteration in the ovarian tumor exome that
was not present in the germline DNA sequence was called a
somatic mutation and included both non-synonymous and
synonymous changes. In the exome mutation data published
by the TCGA consortium, a total of 19,356 somatic mutations
were identified in the cohort, and most independently validated
by a second assay using whole-genome amplification of a
second sample from the same tumor [9]. Mutations that were
not independently validated were computationally evaluated
and had a high likelihood to be true mutations as described [9].
Based on TCGA mutation calls explained above, the total
number of somatic mutations in the tumor exome (Nmut) was
determined for each case (Table S1). Affymetrix SNP6
genotyping data and updated clinical information were obtained
from the TCGA data portal (http://tcga-data.nci.nih.gov/tcga/,
dbGaP accession no. phs000178.v5.p5, acquired 2011 Oct
27). BRCA1 and BRCA2 gene mutation status, BRCA1 and
RAD51C methylation status and ethnic/racial information were
acquired from the cBIO SU2C data portal (http://
cbio.mskcc.org/su2c-portal/).
Clinical assessment of therapy response
All patients underwent debulking surgery prior to platinum
and taxane-based chemotherapy. The outcome of debulking
surgery was the presence or absence of visible residual
disease at the end of surgery; in TCGA the dimensions of
residual disease were estimated. All patients received
platinum-based chemotherapy after surgery. Chemotherapy
resistance was defined as disease progression during first-line
platinum-based chemotherapy or progression within 6 months
after completion of first-line therapy [25]. Chemotherapy
sensitivity was defined as progression-free survival longer than
6 months.
Bioinformatics analysis
Affymetrix SNP6 array data for tumor-normal pairs were
normalized using the Aroma CRMAv2 algorithm, and B-allele
fraction (BAF) was adjusted using the CalMaTe and
TumorBoost Aroma packages[26-28]. Processed data were
analyzed for LOH, allelic imbalance, copy number changes and
normal cell contamination using ASCAT[29], as described
elsewhere [12,29]. Nmut was determined by counting all
mutation calls for each sample reported by the TCGA
consortium (Table S1). Mutations include missense, nonsense,
silent, frameshift and splice variants [9]. The median value for
Nmut was determined for the cohorts and high Nmut was
defined as those values above the median, and low Nmut was
values equal to or below the median. Correlation was
determined by the Spearman rank correlation coefficient.
Statistical significance was assessed by the Wilcoxon rank-
sum test for two-group comparison or by Kruskal-Wallis test for
multiple-group comparison. Survival analysis was performed
using Kaplan-Meier analysis and Cox regression. For Kaplan-
Meier analysis, Nmut was dichotomized around its median
value in study cohorts. In Cox regression, Nmut is continuous,
but hazard ratio (HR) is reported per 10 mutations. The
variables for multivariate analysis included Nmut, age, stage (II,
III, IV), and residual disease (not visible, < 1 cm, 1-2 cm, and >
2 cm). All P values are 2-sided, and all bioinformatics analysis
was performed in the R 2.15.2 statistical framework.
Supporting Information
Table S1.  Genomic and ethnic/race information of TCGA
ovarian cancer cohort used in the present study.
(TXT)
Figure S1.  A) Total number of exome mutations (Nmut) in
high-grade serous ovarian cancer carrying wtBRCA or
mutated BRCA1/2 genes(s) (mBRCA). The tumor Nmut is
presented by dot plots. Median and 25-75 percentiles are
indicated by horizontal lines. P-value is derived from Wilcoxon
rank-sum test. B-C: Tumors were separated into Nmut high
and low groups defined by the median Nmut across the whole
cohort and compared to the rate of chemotherapy resistance.
The significance of the differences was determined by Fisher’s
exact test. OR: Odds Ratio. Confidence intervals in brackets.
B) mBRCA, C) wtBRCA.
(TIF)
Figure S2.  Nmut and survival in mBRCA cases based on
germline or somatic origin of the BRCA1/2 mutation. A)
Total number of exome mutations (Nmut) in high-grade serous
ovarian cancer carrying mutated BRCA1/2 genes(s) of either
germline or somatic origin. The tumor Nmut is presented by dot
plots. Median and 25-75 percentiles are indicated by horizontal
lines. P-value is derived from Wilcoxon rank-sum test. B) and
C) Kaplan-Meier analysis comparing PFS (B) and OS (C)
between serous ovarian cancer patients with either germline or
somatic mBRCA.
(TIF)
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Figure S3.  Position of mutations in BRCA1 and BRCA2
proteins by amino acid number, and their association with
Nmut. A) and B) shows BRCA1 (A) and BRCA2 (B), with the
domains of BRCA1 and BRCA2 proteins illustrated with
different colors on top of each panel. The Y-axis shows for
each mBRCA tumor Nmut, with the corresponding position of
the BRCA1/2 mutation indicated on the X-axis. Germline
mutations are indicated in blue, somatic in red. Missense
mutaitons are shown as diamonds. C) and D) shows Nmut by
grouping the locations of BRCA mutiations according to
relevant regions in BRCA1 and BRCA2, respectively. Red
dotted lines on A) and B) shows the exact grouping cut-offs. P-
values comparing Nmut by location is determined by a Kruskal-
Wallis test.
(TIF)
Figure S4.  Nmut by BRCA1/2 mutations status, and by
BRCA1 or RAD51C methylation status. P-value is based on
a Wilcoxon test, and compares each group to wtBRCA
independently.
(TIF)
Figure S5.  Correlation of tumor Nmut with patient age at
the time of diagnosis. A) germline BRCA1/2 mutation
carriers. B) germline or somatic BRCA1/2 mutations. C)
wtBRCA tumors. Correlation between age and Nmut is
determined by Spearman’s rank correlation coefficient.
(TIF)
Figure S6.  A) and B), correlation between tumor Nmut and
the fraction of the genome with LOH (FLOH). C) and D),
correlation between tumor Nmut and the number of
chromosome arms with telomeric allelic imbalance events
(NtAI). BRCA genotype (mBRCA and wtBRCA) indicated
above each panel.
(TIF)
Figure S7.  The influence of post-surgery residual disease
on progression-free and overall survival in ovarian cancer
using Kaplan-Meier analysis to compare patients with to
patients without residual disease. A) and B) mBRCA
tumors. C) and D) wtBRCA tumors.
(TIF)
Figure S8.  Tumor Nmut and clinical treatment outcome in
ovarian cancer patients with mBRCA tumors and residual
disease or no residual disease. A) and B) Kaplan-Meier
analysis compared PFS and OS between high and low Nmut in
ovarian cancer patients with mBRCA and no residual disease
following debulking surgery. C) and D) PFS and OS between
high and low Nmut in ovarian cancer patients with mBRCA and
residual disease following debulking surgery. High and low
Nmut is defined by median Nmut of all mBRCA cases.
(TIF)
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